Mizuho Raises Icon (NASDAQ:ICLR) Price Target to $160.00

Icon (NASDAQ:ICLR) had its target price increased by research analysts at Mizuho from $154.00 to $160.00 in a research note issued to investors on Tuesday, The Fly reports. The firm presently has a “buy” rating on the medical research company’s stock. Mizuho’s price objective indicates a potential upside of 12.07% from the stock’s previous close.

ICLR has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Icon from a “hold” rating to a “buy” rating and set a $157.00 price objective on the stock in a research report on Thursday, May 30th. BidaskClub upgraded shares of Icon from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 30th. Finally, ValuEngine cut shares of Icon from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. Icon presently has a consensus rating of “Buy” and an average price target of $155.11.

Shares of ICLR opened at $142.77 on Tuesday. Icon has a fifty-two week low of $118.10 and a fifty-two week high of $155.33. The firm has a market capitalization of $7.69 billion, a P/E ratio of 22.70, a price-to-earnings-growth ratio of 1.96 and a beta of 0.55. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.30.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.03. Icon had a net margin of 12.56% and a return on equity of 25.71%. The company had revenue of $674.85 million for the quarter, compared to analysts’ expectations of $668.93 million. During the same quarter in the previous year, the business posted $1.44 earnings per share. Icon’s quarterly revenue was up 8.8% on a year-over-year basis. As a group, analysts anticipate that Icon will post 6.87 EPS for the current year.

A number of hedge funds have recently bought and sold shares of ICLR. Marshall Wace North America L.P. boosted its stake in shares of Icon by 992.4% during the first quarter. Marshall Wace North America L.P. now owns 45,358 shares of the medical research company’s stock valued at $6,195,000 after purchasing an additional 41,206 shares during the period. Clearbridge Investments LLC boosted its stake in shares of Icon by 5.9% during the first quarter. Clearbridge Investments LLC now owns 2,353,035 shares of the medical research company’s stock valued at $321,378,000 after purchasing an additional 130,954 shares during the period. BTC Capital Management Inc. purchased a new stake in shares of Icon during the first quarter valued at $204,000. BlueMountain Capital Management LLC boosted its stake in shares of Icon by 213.2% during the first quarter. BlueMountain Capital Management LLC now owns 33,225 shares of the medical research company’s stock valued at $4,538,000 after purchasing an additional 22,617 shares during the period. Finally, Covenant Partners LLC purchased a new stake in shares of Icon during the first quarter valued at $542,000. Institutional investors and hedge funds own 85.75% of the company’s stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Further Reading: How Do Mutual Funds Work?

The Fly

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.